Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems.
The efficacy of boosted protease inhibitor monotherapy (BPIm) in HIV-positive patients with complex medical problems was assessed in ten patients. With BPIm, median (range) HIV viral load reduction was log10 2.15 (1.62-3.1) by 4-8 weeks; in four patients, viral load was < 400 copies/ml. During follow-up, at median (range) = 50 (8-156) weeks, no patient had an opportunistic illness; one patient developed new PI mutations after 48 weeks. These very preliminary data need further confirmation on a larger scale.
Garrett
Nigel J
NJ
Mortimer Market Centre, London, UK.
Matin
Nasha
N
Edwards
Simon G
SG
Miller
Robert F
RF
D000208:Acute Disease; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000075202:Contraindications; D016638:Critical Illness; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019562:Viral Load
D017320:HIV Protease Inhibitors